

Editor's page

Revista Española de Cardiología 2022

Revista Española de Cardiología 2022

Juan Sanchis,^{a,*} Pablo Avanzas,^b David Filgueiras-Rama,^b Pablo García-Pavía,^b and Laura Sanchis^b^aEditor-in-Chief, Revista Española de Cardiología^bAssociate Editor, Revista Española de Cardiología

The current editorial team began its 3-year tenure at the Congress of the Spanish Society of Cardiology (SEC) held in Zaragoza at the end of October 2021. Now, as every year,^{1,2} it is time to summarize the journal's activity in the last 12 months. First, we would like to thank the editorial office (Eva M. Cardenal, María González Nogal, Helena Gómez-Lobo, and Belén Juan), led by our editorial director, Iria del Río, for their excellent professionalism in ensuring an orderly transition between teams.

EDITORIAL ACTIVITY

Figure 1 shows the number of articles received in 2022. Of note, the number of submissions decreased markedly, particularly original articles and scientific letters. There is no clear explanation for this. The most plausible reason is that submissions significantly increased in the year of the COVID-19 pandemic outbreak. Indeed, **Figure 1** illustrates the historical peak in the submission of original articles and scientific letters in 2020. Conceivably, research groups need new data to restart production. There were some initial signs of a recovery at the end of 2022, as shown in **Figure 2**. In addition, and with the aim of boosting publication activity, *Rev Esp Cardiol* has promoted the involvement of young cardiologists in research and publication (see below). In addition, we have decided to actively invite internationally known groups working on experimental cardiology to submit research articles to *Rev Esp Cardiol*. All of this, together with the journal's high impact factor (IF) in the 2021 Journal Citation Reports (2022 release), lead us to feel optimistic that submissions will increase in the near future.

Most of the articles (53%) continue to be submitted from Spain, while 13% are from other European countries, 15% from Latin America, less than 1% from North America, and 18% from other countries (mainly Asia).

THE REVIEW PROCESS AND REVIEW TIMES

Reviewers' commitment to *Rev Esp Cardiol* is one of its main assets. The virtues of our review process are its quality and speed. **Table 1** and **Table 2** list *Rev Esp Cardiol* reviewers in 2022 and our elite reviewers (September 2021 – August 2022). We would like to

SEE RELATED CONTENT:

<https://doi.org/10.1016/j.rec.2023.01.005>

* Corresponding author.

E-mail address: rec@revespcardiol.org (J. Sanchis).

@RevEspCardiol

extend our most sincere gratitude and appreciation to all of them. **Figure 3** shows the review times of the first submitted version of the manuscripts in 2022, which are excellent and fairly similar to those of 2021. We believe that shorter times would probably be incompatible with a thorough review.

CHANGES TO REV ESP CARDIOL IN 2022

New newsletter

Newsletters have become central for readers of scientific journals. Currently, they are the primary vehicle for spreading newly published articles. With this in mind, we have completely renewed *Rev Esp Cardiol* newsletters as follows: *a)* the content is separated according to the language of the articles, with English at the top of the newsletter and Spanish at the bottom; thus, readers can directly access their preferred language; *b)* articles are classified and grouped according to their specific field, identified by a section heading; *c)* a central illustration is included for each original, review and special article; *d)* the number of listed authors per article has been reduced to two (first and last) to avoid a wordy presentation; and *e)* the header *Rev Esp Cardiol* is now more visible.

The first revamped newsletter was sent to our subscribers on April 26, 2022. The initial feedback was fairly positive as per the number of articles downloaded, with a significant and sustained increase.

Central illustration

Many journals have now introduced a central illustration in original articles. The goal is to show the main result of the study in a graphic and appealing design. *Rev Esp Cardiol* joined this trend in 2022, presenting central illustrations in the newsletter and website. We hope our readers find this initiative attractive.

Mean time between acceptance and publication

Authors appreciate speed between acceptance of their articles and their availability in Medline. In addition, knowledge is disseminated to the scientific community earlier. So far, the first format through which *Rev Esp Cardiol* articles could be accessed via Medline was the ahead-of-print publication of the English version. The production of an ahead-of-print article takes around 40 days. Despite the efforts of our editorial office and publisher, we were unable to shorten this production time and so we took the




Figure 1. Original articles, scientific letters and images in cardiology submitted to *Rev Esp Cardiol* in 2022.




Figure 2. Original articles submitted to *Rev Esp Cardiol* monthly, 2021-2022.

Table 1

Revista Española de Cardiología reviewers in 2022

Omar Abdul-Jawad
César Abelleira
Emad Abu-Assi
Juan Acosta
Alejandro Adsuar
Jazmín Aguado
Finn Akerström
Arístides Alarcón
Alejandro Alcaine
Manuel Alcázar
Guillermo Aldama
Jorge Alegre
Josep M. Alegret
Fernando Alfonso
Joaquín Alonso
Gonzalo L. Alonso-Salinas
Pau Alonso
Rodrigo Alonso
Rafael Alonso-González
Alberto Alperi
Miguel Álvarez

Table 1 (Continued)

Revista Española de Cardiología reviewers in 2022

Jesús Álvarez-García
Ignacio J. Amat
Dominick Angiolillo
Ignasi Anguera
Manuel P. Anguita
Eduardo Arana
Miguel Á. Arias
Albert Ariza
Pedro Armario
Vicente Arrarte
Ramón Arroyo
Dabit Arzamendi
Juan J. Badimón
Enrique J. Balbacid
José Banegas
Adrian Baranchuk
Alfredo Bardají
Eduardo Barge-Caballero
Gonzalo Barge-Caballero
José Barrabés
Ana Barradas

Table 1 (Continued)

Revista Española de Cardiología reviewers in 2022

Manuel Barreiro
Roberto Barriales
Antonio Barros
Teresa Bastante
Pablo Bastos
Javier Bautista
Antoni Bayés de Luna
Antoni Bayés-Genís
Víctor Bazán
Begoña Benito
Alberto Berenguer
Francisco J. Bermúdez
J. Luis Bernal
José R. Berrazueta
Antonio Berruezo
Giuseppe Biondi
Manuel Blanco
Zorba Blázquez
Vicente Bodí
Clara Bonanad
Araceli Boraita
Luis Borrego
Xavier Bosch
Ramón Bover
Montserrat Bret
María Brion
Sem Briangos
Josep Brugada
Héctor Bueno
Pilar Cabanas
Ramón Calviño
Francisco E. Calvo
David Calvo
Óscar Campuzano
Raquel Campuzano
Óscar Cano
Victoria Cañas
Pedro Caravaca
Juan Caro
Amelia Carro
Antonio Cartón
Víctor Castro
Pilar Cejudo
Ángel R. Cequier
Marina Cerrone
Marinela Chaparro
Fernando Civeira
Marta Cobo
Miguel Á. Cobos
Antonio Coca
Josep Comín
Luciano Consuegra
Alberto Cordero
Juan Cosín-Sales
Eliecer Coto
Javier Courel
David Couto

Table 1 (Continued)

Revista Española de Cardiología reviewers in 2022

Ignacio Cruz
Héctor Cubero
José I. Cuende
Emilio Cuesta
José Curbelo
Regina Dalmau
Tomás Datino
José A. de Agustín
Fernando de Frutos
Javier De Juan Bagudá
Rafael E. De la Espriella
Jesus M. de la Hera
José M. de la Torre-Hernández
Giovanni Luigi De María
Irene R. Dégano
Juan F. Delgado
Beatriz Díaz-Molina
José F. Díaz
Leonel Díaz-González
Jesús Díaz-Gutiérrez
Elena Díaz-Peláez
Javier Díez
Pablo Díez-Villanueva
David Dobarro
Adelina Doltra
Blanca Domenech
Fernando Domínguez
Alberto Domínguez-Rodríguez
Laura Dos
Julio C. Echarte
Sonia Eiras
Rocío Eiros
Jaime Elizaga
Daniel Enríquez
Carlos Escobar
Laura Escolà-Vergé
M. Pilar Escribano
Juan M. Escudier
Alberto Esteban
Rodrigo Estévez
Vicente Estrada
Artur Evangelista
Núria Farré
Marta Farrero
José A. Fernández-Díaz
Carlos Fernández-Palomeque
Ángel L. Fernández
Juan Fernández-Armenta
Leticia Fernández-Friera
Covadonga Fernández-Golfín
Ignacio Fernández-Lozano
Diego Fernández-Rodríguez
Marcos Ferrández-Escarabajal
Ignacio Ferreira-González
José L. Ferreiro
Carlos Ferrera
Xacobe Flores

Table 1 (Continued)

Revista Española de Cardiología reviewers in 2022

Adolfo Fontenla
José F. Forteza
Eduardo Franco
Xavier Freixa
Luigi Gabrielli
Carlos Galán
Laura Galián
Maria Gallego-Delgado
Ana García-Álvarez
Bruno García del Blanco
Alba García-Escalonado
Rocío García-Orta
Ignacio García-Bolao
Alberto García-Lledó
Inés García-Lunar
Xavier García-Moll
Antonio García-Quintana
José A. García-Robles
Juan Gimeno
Josébe Goirigolzarri-Artaza
Dulcenombre Gómez-Garre
M. Carmen Gómez-Rubín
Manuel Gómez-Bueno
Juan J. Gómez-Doblas
Joan A. Gómez-Hospital
José González-Costello
Arantxa González-Miqueo
Álvaro González-Rocafort
José M. González-Santos
Juan J. González-Ferrer
Violeta González-Salvado
Francisco González-Vílchez
José L. Górriz
John Graham
Antonio Grande
Pilar Guallar
Eduard Guasch
José Guerra
Enrique Gutiérrez-Ibañes
José Gutiérrez
Gabriela Guzmán-Martínez
Jordi Heijman
Iván Hernández-Betancor
Felipe Hernández-Hernández
Francisco J. Hernández-Pérez
Daniel Hernández-Vaquero
Ignacio Iglesias-Gárriz
José Jalife
Santiago Jiménez-Valero
Carmen Jiménez
Javier Jiménez-Candil
Juan Jiménez-Jáimez
Manuel F. Jiménez-Navarro
Justo Juliá
Alfonso Jurado-Román
Juan C. Kaski
Adnan Kastrati

Table 1 (Continued)

Revista Española de Cardiología reviewers in 2022

Won-Keun Kim
Giulio La Rosa
Enrique Lara
María Lázaro
Pablo Loma-Osorio
Teresa López-Fernández
José López-Haldón
Diego López-Otero
Javier López
Esteban López-de-Sá
Ramón López-Palop
Rebeca Lorca
Gerard Loughlin
Íñigo Lozano
María Luaces
Álvaro Macías
Begoña Manso
Francisco Marín
Manuel Marina
Manlio F. Márquez
Carlos E. Martín
María Martín
Laura Martínez-Mateu
Pedro Martínez
Isaac Martínez-Bendayán
José L. Martínez-Sande
Manuel Martínez-Sellés
Lluís Masana
María D. Masiá
Andrea Mazzanti
Hernán D. Mejía
Ana Méndez
Irene Méndez
Guionmar Mendieta
Dolores Mesa-Rubio
Ángel L. Miracle
Javier Modrego
Pedro Moliner
Emilio Monguió
Lorenzo Monserrat
Juan M. Monteagudo
Vanessa Moñivas
Raúl Moreno
César Morís
Guillermo Muñiz
Antonio J. Muñoz
José Nativi
Luis Nombela
Francisco J. Noriega
Julio Núñez
Iván J. Núñez-Gil
Soledad Ojeda
Carmen Olmos
Peter Ong
Marta Ortega
Carolina Ortiz
Joaquín Osca

Table 1 (Continued)

Revista Española de Cardiología reviewers in 2022

Teresa Padró
Julián Palacios
Julián Palomino
Manuel Pan
Ana Pardo
Isaac Pascual
Salvador Pedraza
Rafael Peinado
Laura Peña
María L. Peña
Daniel Pereda
Leopoldo Pérez de Isla
Armando Pérez de Prado
Diego Pérez
Esther Pérez-David
Carlos N. Pérez-García
Antonia Pijuan
Inés Ponz de Antonio
Eduardo Pozo
Raquel Prieto
Juan Puig
Juan Quiles
Antonio Ramos-Martínez
Diego Rangel
Sergio Raposeiras-Roubín
Susana Ravassa
Elena Refoyo
Ander Regueiro
María A. Restrepo
Juan R. Rey
Juan J. Ríos
Tomás Ripoll
Mercedes Rivas
José Rivera
Fernando Rivero
Ivo Roca-Luque
Moisés Rodríguez-Mañero
José F. Rodríguez-Palomares
Inmaculada Roldán
Nieves Romero
José Rozado
Fernando Rueda
José Ruiz-Cantador
Ricardo Ruiz-Granell
María J. Ruiz-Cano
Juan M. Ruiz-Nodar
Manel Sabaté
Ricardo Salgado
Rafael Salguero
Luisa Salido
Jorge Salinas
Pablo Salinas
Óscar Salvador
José A. San Román
Pedro L. Sánchez
Javier Sánchez-González
Ángel Sánchez-Recalde

Table 1 (Continued)

Revista Española de Cardiología reviewers in 2022

Enrique Santas
Carlos García Santos-Gallego
María Sanz de la Garza
Javier Sanz
Fernando Sarnago
Georgia Sarquella
Inés Sayago
Javier Segovia
Lorenzo Silva
Jacobo Silva
Alessandro Sionis
Marta Sitges
Maite Subirana
Gabriela Tirado
Jorge Toquero
Javier Torres
Leire Unzué
Aitor Uribarri
Félix Valencia
Alfonso Valle
Israel Valverde
Luca Vannini
Ravi Vazirani
Rafael Vázquez-García
Ana Viana
Rafael Vidal
Maite Vidán
Isidre Vilacosta
Ricardo Vivancos
David Vivas
Sergi Yun
Juan I. Zabala
Elisabet Zamora
Manuel Zarzoso
Eduardo Zatarain

Table 2

Elite reviewers 2022

Fernando Alfonso
Juan Caro
Luciano Consuegra
Alberto Cordero
Pablo Díez-Villanueva
Juan J. Gómez-Doblas
Enrique Gutiérrez-Ibañes
Manuel Jiménez-Navarro
Esteban López-de-Sá
Ramón López-Palop




Figure 3. Time to first decision (days) and review times, both overall and for original articles exclusively.

initiative of producing an uncorrected version of our articles (pre-proof) immediately after their acceptance. Overall, this format makes articles available approximately 17 days after acceptance on the *Rev Esp Cardiol* website and ScienceDirect and about 14 days later on Medline. This does not apply to articles submitted in Spanish, since Medline only indexes the English edition of *Rev Esp Cardiol*. Consequently, articles submitted in Spanish must wait for their English translation for publication on Medline.

Education and young cardiologists

A central objective of scientific journals should be education, which should not be overshadowed by bibliometric interests. Indeed, we have continued and increased the publication of reviews and consensus documents considered of interest to the cardiology community^{3–13} and the official reports of the national registries of pacemakers,¹⁴ implantable automatic defibrillators,¹⁵ heart transplant,¹⁶ cardiac catheterization and interventional cardiology,¹⁷ and catheter ablation.¹⁸ Starting this year, the translated version of the ESC guidelines will be available on the SEC website rather than in *Rev Esp Cardiol*.

The editorial team believes that it is essential to involve young cardiologists in research. To this end, we created 2 new awards for the best articles published in *Rev Esp Cardiol* by a cardiologist of 40 years or younger and a resident in addition to the annual SEC awards for the best published articles (Table 3). Likewise, at the 2022 SEC Congress held in Palma de Mallorca, the editors delivered a seminar on designing and conducting a research project and writing a scientific article. In addition, in 2022 *Rev Esp Cardiol* published the best clinical case of the 2022 SEC Clinical Case League in the form of a scientific letter, accompanied by an editorial comment emphasizing its educational value.^{39,40} *Rev Esp Cardiol* is now preparing the 2023 edition. We hope that all these initiatives will increase awareness among young cardiologists and residents of the importance of research.

Website and social media

Our website is an undisputed reference for information on cardiology in Spanish.⁴¹ In 2022, our digital edition was consulted by more than 5.7 million users, with a total of almost 13 million page views. In ScienceDirect, *Rev Esp Cardiol* articles exceeded 1 million visits to our Spanish and English articles. There were also the views and downloads from other repositories. Most of the traffic comes from the prominent positioning of our articles in search engines (91.4% organic traffic), followed by direct searches and links from other websites.

Table 3

Articles receiving an award from the Spanish Society of Cardiology in 2022

1. Prizes awarded by the Spanish Society of Cardiology for articles published in *Rev Esp Cardiol* in 2021

First prize

Morentin B, et al. Sports-related sudden cardiac death in Spain. A multicenter, population-based, forensic study of 288 cases. *Rev Esp Cardiol*. 2021¹⁹

Second prize

Barriales-Villa R, et al. Risk predictors in a Spanish cohort with cardiac laminopathies. The REDLAMINA registry. *Rev Esp Cardiol*. 2021²⁰

2. Prizes awarded by the Spanish Society of Cardiology for the articles published in *Rev Esp Cardiol* with the greatest international impact

Most-cited articles, long-term

First prize

Aranceta-Bartrina J, et al. Prevalence of General Obesity and Abdominal Obesity in the Spanish Adult Population (Aged 25–64 Years) 2014–2015: The ENPE Study. *Rev Esp Cardiol*. 2016²¹

Second prize

Menéndez E, et al. Prevalence, Diagnosis, Treatment, and Control of Hypertension in Spain. Results of the Di@bet.es Study. *Rev Esp Cardiol*. 2016²²

Most-cited articles, midterm

First prize

Hernaez A, et al. Excess Weight in Spain: Current Situation, Projections for 2030, and Estimated Direct Extra Cost for the Spanish Health System. *Rev Esp Cardiol*. 2019.²³

Second prize

Na SJ, et al. Vasoactive Inotropic Score as a Predictor of Mortality in Adult Patients With Cardiogenic Shock: Medical Therapy Versus ECMO. *Rev Esp Cardiol*. 2019.²⁴

3. Prize awarded by the Spanish Society of Cardiology for the best article published in *Rev Esp Cardiol* by a first author ≤ 40 years old

López - Sainz A, et al. Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center. *Rev Esp Cardiol*. 2021²⁵

4. Prize awarded by the Spanish Society of Cardiology for the best article published in *Rev Esp Cardiol* by a resident in a Spanish center

Sánchez Vega JD, et al. Temporal trends in postinfarction ventricular septal rupture: the CIVIAM Registry. *Rev Esp Cardiol*. 2021²⁶

5. Prize awarded by the Spanish Society of Cardiology for the best article published in REC: CardioClinics

Plata-Mosquera CA, et al. Sacubitril/valsartan reduces levels of procollagen types I and III and correlates with reverse cardiac remodeling. *REC CardioClinics*. 2021²⁷

6. Prize awarded by the Interventional Cardiology Association for the best article published in REC: Interventional Cardiology

First prize

van Zandvoort IJC, et al. Predictors of postprocedural fractional flow reserve: insights from the FFR-SEARCH study. *REC Interv Cardiol*. 2021²⁸

Second prize

Cepas-Guillén PL, et al. Outcomes of nonagenarians after transcatheter aortic valve implantation. *REC Interv Cardiol*. 2021²⁹

Table 3 (Continued)

Articles receiving an award from the Spanish Society of Cardiology in 2022

7. Prizes awarded by the Clinical Cardiology Association for the best articles published in Rev Esp Cardiol

López-Sainz A, et al. Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center. *Rev Esp Cardiol.* 2021²⁵

Martín García A, et al. Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC. *Rev Esp Cardiol.* 2021³⁰

8. Prize awarded by the Ischemic Heart Disease and Acute Cardiac Care Association for the best article published in Rev Esp Cardiol

Sánchez-Salado JC, et al. Trends in cardiogenic shock management and prognostic impact of type of treating center. *Rev Esp Cardiol.* 2020³¹

9. Prize awarded by the Cardiovascular Risk and Rehabilitation Association for the best publication

Castro-Conde A, et al. Feasibility and results of an intensive cardiac rehabilitation program. Insights from the MxM (Más por Menos) randomized trial. *Rev Esp Cardiol.* 2021³²

10. Prize awarded by the Heart Rhythm Association for the best article published in Rev Esp Cardiol

Loughlin G, et al. Predictors of adoption and impact of evidence-based programming on the incidence of implantable cardioverter-defibrillator therapies. *Rev Esp Cardiol.* 2021³³

11. Prize awarded by the Pediatric Cardiology and Congenital Heart Disease Section for the best article published in Rev Esp Cardiol

Rueda Soriano J, et al. Time course and predictors for neoaortic root dilatation and neoaortic valve regurgitation during adult life after arterial switch operation. *Rev Esp Cardiol.* 2021³⁴

12. Prize awarded by the Section on Familial Heart Disease and Cardiovascular Genetics for the best article published in Rev Esp Cardiol

Barriales-Villa R, et al. Risk predictors in a Spanish cohort with cardiac laminopathies. The REDLAMINA registry. *Rev Esp Cardiol.* 2021²⁰

13. Prizes awarded by the Cardiac Imaging Association for the best articles published

Gamaza S, et al. Prognostic value of aortic valve area normalized to body size in native aortic stenosis. *Rev Esp Cardiol.* 2021³⁵

Urmeneta J, et al. Myocardial strain in nonischemic dilated cardiomyopathy with feature tracking. Feasibility and prognostic implications. *Rev Esp Cardiol.* 2021³⁶

14. Magda Heras prize for the best article published in an Iberoamerican cardiovascular journal*First prize*

Morentin B, et al. Sports-related sudden cardiac death in Spain. A multicenter, population-based, forensic study of 288 cases. *Rev Esp Cardiol.* 2021¹⁹

Second prize

Santos IS, et al. Atrial Fibrillation Diagnosis using ECG Records and Self-Report in the Community: Cross-Sectional Analysis from Elsa-Brasil. *Arq Bras Cardiol.* 2021³⁷

Third prize

Jimena Gamgarde M, et al. Comparación pronóstica entre scores de riesgo y la aplicación de redes neuronales para la predicción de la mortalidad a corto y mediano plazo en pacientes con insuficiencia cardiaca. *Rev Argent Cardiol.* 2021³⁸

Starting in 2023, there have been some notable innovations regarding the Editor's videos: they have been shortened to 2 minutes and, instead of the previous author-editor interview, one of the authors now takes on the leading role, directly presenting the main findings of the research article. Our idea is to facilitate views on mobile devices and social media and optimize the integration of these materials in CardioTV, the audiovisual SEC ecosystem. *Rev Esp Cardiol* will continue the regular publication of author interviews on the *Rev Esp Cardiol Blog*,⁴³ on the SEC website and their presence in SEC News and other SEC bulletins.

Registries

Registries are an essential source of research activity. They often involve multiple centers and patients. Consequently, coordination and data management require considerable effort by principal investigators and these articles deserve publication of the results in a top journal like *Rev Esp Cardiol*. For this purpose, proper design and high-quality data are essential. In a recent Editor's page, we expressed concerns about self-reported, unaudited registries submitted to *Rev Esp Cardiol*.⁴⁴ In summary, our thoughts are as follows: *a*) a registry should address not only what is already known in a particular context but also some novel features; *b*) the availability of electronic clinical histories allows homogeneity of data acquisition among centers, in terms of a reproducible flowchart for screening and recruitment, and facilitates follow-up.⁴⁵ Therefore, the final article should present a flowchart and the completeness of the follow-up. Furthermore, these articles will now have to include information on participating centers, listing the principal investigator in each center who is responsible for the accuracy of the data.

BIBLIOMETRIC NEWS

IF is often considered the universal quality index of scientific journals. *Rev Esp Cardiol* reached its historical IF peak last year, positioning the journal in the first quartile of the Cardiac and Cardiovascular Systems category. We acknowledge the excellent job of the previous editorial team. Without denying its value as the first marker of a scientific journal, IF is widely recognized to be an imperfect metric.⁴⁶ This index can be increased or decreased by unexpected circumstances. Furthermore, the system for measuring IF is changing, and, starting in 2020, early access is gradually being added to Journal Citation Reports. This onboarding process is not simultaneous for all journals and, until it finishes, which may take years, IF may become unstable. We are paying close attention to changes in the IF of *Rev Esp Cardiol* without forgetting other quality indexes or the journal's educational objectives.

FUTURE OF REV ESP CARDIOL

In 2022 we celebrated 75 years of *Rev Esp Cardiol*, providing us with an opportunity to reflect on what has been achieved during these years and the future of the journal. The scenario of cardiology journals has become highly competitive. The leading journals have created an extensive network of excellent family journals, while new journals, mostly open-access, have also been launched. Traditional journals face difficulties in jostling for a space in this highly competitive field. The situation is even more challenging for national journals like *Rev Esp Cardiol*. We created our sister journals (*REC: CardioClinics*⁴⁷ and *REC: Interventional Cardiology*⁴⁸) in 2018 to allow the publication of more submitted articles. We also have an international mission, and some initiatives this year went in this direction. However, Spanish investigators constitute our

During the last year, we have been intensely active on social media, mainly on Twitter, the preferred social platform of cardiologists worldwide. The number of followers of the REC Publications Twitter profile⁴² has increased (20 380 at the beginning of 2023), and efforts have been made to tag article authors, who now also have the possibility of including their Twitter account information in their articles. Last year, we incorporated the creation of threads and increased our multimedia content, with central illustrations to make the articles more attractive to read and enhance their dissemination. We would like to thank the REC Publications' ICT consultant, Juan Quiles, for his excellent work.

primary target. They are the main asset of *Rev Esp Cardiol*, and their contribution is essential for the future. From these lines, we would like to encourage them to continue supporting *Rev Esp Cardiol*, and our commitment is to respond to this engagement.

ACKNOWLEDGEMENTS

Once again, we must mention the work of the translation and proofreading teams, whose professionalism allows the journal to continue to be bilingual. For the English version, we continue to count on the translation team composed of Simon Bartlett, Helen Casas, Celine Cavallo, Kevin Clayton, Simon Coxon, Jane Marshall, and Anne Murray, coordinated by Gail Craigie as copyeditor. We also thank all the departments of *Casa del Corazón* for their help and support in increasing the prominence of our journal; José Luis Vázquez, responsible for audiovisuals at the SEC, deserves special mention for his enthusiasm and professionalism in new *Rev Esp Cardiol* projects, as does Fernando Fernández, director of the IT department, for his collaborative vision and valuable insights.

Finally, we would like to dedicate this article to our beloved Azucena Saavedra, our journal manager in Elsevier since 2017, whose loss in December 2022 filled us with sadness. May these lines serve to thank her for her great work, which has been instrumental in helping our journal to achieve many successes over the years, including those presented on this Editors' Page.

FUNDING

None received.

CONFLICTS OF INTEREST

None declared.

REFERENCES

1. Ferreira-González I, Sánchez-Recalde Á, Abu-Assi E, Arias MA, Gallego P. A fond farewell from the editors of Revista Española de Cardiología 2015–2021. *Rev Esp Cardiol.* 2021;74:451–461.
2. Sanchis J, Avanzas P, Filgueiras-Rama D, et al. New new perspectives. *Rev Esp Cardiol.* 2022;75:431–439.
3. Requena-Ibáñez JA, Santos-Gallego CG, Badimón JJ. SGLT2i in heart failure: can their benefits be expanded across the entire spectrum of ejection fraction? *Rev Esp Cardiol.* 2022;75:833–841.
4. Bañeras J, Iglesias-Grau J, Téllez-Plaza M, et al. Environment and cardiovascular health: causes, consequences and opportunities in prevention and treatment. *Rev Esp Cardiol.* 2022;75:1050–1058.
5. Casas G, Rodríguez-Palomares JF, Ferreira-González I. Left ventricular noncompaction: a disease or a phenotypic trait? *Rev Esp Cardiol.* 2022;75:1059–1069.
6. de la Espriella R, Cobo M, Santas E, et al. Assessment of filling pressures and fluid overload in heart failure: an updated perspective. *Rev Esp Cardiol.* 2023;76:47–57.
7. Ferrer-Sistach E, Teis A, Bayés-Genís A, Delgado V. Multimodality imaging in aortic stenosis: new diagnostic and therapeutic frontiers. *Rev Esp Cardiol.* 2023;76:40–46.
8. Sánchez-Luna JP, Amat-Santos JJ. Interventional management of mechanical complications in acute myocardial infarction. *Rev Esp Cardiol.* 2022. <http://dx.doi.org/10.1016/j.recesp.2022.11.014>.
9. Rossello X, González-Del-Hoyo M. Survival analyses in cardiovascular research, part I: the essentials. *Rev Esp Cardiol.* 2022;75:67–76.
10. Rossello X, González-Del-Hoyo M. Survival analyses in cardiovascular research, part II: statistical methods in challenging situations. *Rev Esp Cardiol.* 2022;75:77–85.
11. Cruz-González I, Estévez-Loureiro R, Barreiro-Pérez M, et al. Mitral and tricuspid valve disease: diagnosis and management. Consensus document of the Section on Valvular Heart Disease and the Cardiovascular Imaging, Clinical Cardiology, and Interventional Cardiology Associations of the Spanish Society of Cardiology. *Rev Esp Cardiol.* 2022;75:911–922.
12. Barreiro-Pérez M, Cabeza B, Calvo D, et al. Magnetic resonance in patients with cardiovascular devices SEC-GT CRMTC/SEC-Heart Rhythm Association/SERAM/SEICAT consensus document. *Rev Esp Cardiol.* 2023;76:183–198.
13. Martínez-Sellés M, Hernández-Pérez FJ, Uribarri A, et al. Cardiogenic shock code 2023. Expert document for a multidisciplinary organization that allows quality care. *Rev Esp Cardiol.* 2022. <http://dx.doi.org/10.1016/j.rec.2022.10.014>.
14. Pombo Jiménez M, Chimeno García J, Bertomeu González V, Cano Pérez Óaue, Spanish pacemaker registry. 19th official report of the Heart Rhythm Association of the Spanish Society of Cardiology (2021). *Rev Esp Cardiol.* 2022;75:946–956.
15. Fernández Lozano I, Osca Asensi J, Alzueta Rodríguez J. Spanish implantable cardioverter-defibrillator registry. 18th official report of the Heart Rhythm Association of the Spanish Society of Cardiology (2021). *Rev Esp Cardiol.* 2022;75:933–945.
16. González-Vilchez F, Gómez-Bueno M, Almenar-Bonet L, et al. Spanish heart transplant registry. 33rd official report of the Heart Failure Association of the Spanish Society of Cardiology. *Rev Esp Cardiol.* 2022;75:923–932.
17. Freixa X, Jurado-Román A, Cid B, Cruz-González I. Spanish cardiac catheterization and coronary intervention registry. 31st official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990–2021). *Rev Esp Cardiol.* 2022;75:1040–1049.
18. Anguera I, Cano Pérez Óaue, Bazán V. Spanish catheter ablation registry. 21st official report of the Heart Rhythm Association of the Spanish Society of Cardiology (2021). *Rev Esp Cardiol.* 2022;75:1029–1039.
19. Morentín B, Suárez-Mier MP, Monzón A, Ballesteros J, Molina P, Lucena J. Sports-related sudden cardiac death in Spain. A multicenter, population-based, forensic study of 288 cases. *Rev Esp Cardiol.* 2021;74:225–232.
20. Barriales-Villa R, Ochoa JP, Larrañaga-Moreira JM, et al. Risk predictors in a Spanish cohort with cardiac laminopathies. The REDLAMINA registry. *Rev Esp Cardiol.* 2021;74:216–224.
21. Aranceta-Bartrina J, Pérez-Rodrigo C, Alberdi-Aresti G, Ramos-Carrera N, Lázaro-Masedof S. Prevalence of General Obesity and Abdominal Obesity in the Spanish Adult Population (Aged 25–64 Years) 2014–2015: The ENPE Study. *Rev Esp Cardiol.* 2016;69:579–587.
22. Menéndez E, Delgado E, Fernández-Vega F, et al. Prevalence, Diagnosis, Treatment and Control of Hypertension in Spain Results of the Dibetes Study. *Rev Esp Cardiol.* 2016;69:572–578.
23. Hernaez A, Zomeño MD, Dégano IR, et al. Excess Weight in Spain: Current Situation. Projections for 2030 and Estimated Direct Extra Cost for the Spanish Health System. *Rev Esp Cardiol.* 2019;72:916–924.
24. Na SJ, Chung CR, Cho YH, et al. Vasoactive Inotropic Score as a Predictor of Mortality in Adult Patients With Cardiogenic Shock: Medical Therapy Versus ECMO. *Rev Esp Cardiol.* 2019;72:40–47.
25. López-Sainz A, Hernandez-Hernandez A, Gonzalez-Lopez E, et al. Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center. *Rev Esp Cardiol.* 2021;74:149–158.
26. Sánchez Vega JD, Alonso Salinas GL, Viéitez Flórez JM, et al. Temporal trends in postinfarction ventricular septal rupture: the CIVIAM Registry. *Rev Esp Cardiol.* 2021;74:757–764.
27. Plata-Mosquera CA, Bernal-Torres W, Herrera-Escandón AA, et al. Sacubitril/valsartan reduces levels of procollagen types I and III and correlates with reverse cardiac remodeling. *REC CardioClinics.* 2021;56:14–21.
28. van Zandvoort IJC, Masjedji K, Neelman T, et al. Predictors of postprocedural fractional flow reserve: insights from the FFR-SEARCH study. *REC Interv Cardiol.* 2021;3:91–97.
29. Cepas-Guillén PL, Regueiro A, Sanmiguel Cervera D, et al. Outcomes of nonagenarians after transcatheter aortic valve implantation. *REC Interv Cardiol.* 2021;3:250–257.
30. Martín García A, Mitro C, Mazón Ramos P, et al. Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC FEC SEOM SEOR SEHH SEMC AEEMT AEC and AECC. *Rev Esp Cardiol.* 2021;74:438–448.
31. Sánchez-Salado JC, Burgos V, Ariza-Solé A, et al. Trends in cardiogenic shock management and prognostic impact of type of treating center. *Rev Esp Cardiol.* 2020;73:546–553.
32. Castro-Conde A, Abeytua M, Arrarte Esteban VI, et al. Feasibility and results of an intensive cardiac rehabilitation program. Insights from the MxM (Más por Menos) randomized trial. *Rev Esp Cardiol.* 2021;74:518–525.
33. Loughlin G, Datino T, Arenas Áaue, et al. Predictors of adoption and impact of evidence-based programming on the incidence of implantable cardioverter-defibrillator therapies. *Rev Esp Cardiol.* 2021;74:296–302.
34. Rueda Soriano J, Rodríguez Puras MJ, Buendía Fuentes F, et al. Time course and predictors for neoaortic root dilatation and neoaortic valve regurgitation during adult life after arterial switch operation. *Rev Esp Cardiol.* 2021;74:329–336.
35. Gamaza S, Díaz Retamino E, Carmona García R, et al. Prognostic value of aortic valve area normalized to body size in native aortic stenosis. *Rev Esp Cardiol.* 2021;74:44–50.
36. Urmeneta J, Pozo Osinalde E, Rodríguez-Hernández JL, et al. Myocardial strain in nonischemic dilated cardiomyopathy with feature tracking. Feasibility and prognostic implications. *Rev Esp Cardiol.* 2021;74:159–166.
37. Santos IS, Lotufo PA, Brant L, et al. Atrial Fibrillation Diagnosis using ECG Records and Self-Report in the Community: Cross-Sectional Analysis from Elsa-Brasil. *Arq Bras Cardiol.* 2021;117:426–434.
38. Jimena Gamgarde M, Higa C, Novo F, et al. Prognostic Comparison between Risk Scores and Neural Networks to Predict Short- and Mid-Term Mortality in Acute Heart Failure. *Rev Argent Cardiol.* 2021;89:435–446.
39. Rojas Brito AB, Cabrera Huerta S, Pérez Nogales ED, Saiz Udaeta B, Rubio García JM. Exertional dyspnea following lumbar microdiscectomy. *Rev Esp Cardiol.* 2022;75:1073–1075.
40. Segovia Cubero J. Learning from clinical cases: a safe bet yesterday and today. *Rev Esp Cardiol.* 2022;75:985–987.

41. Revista Española de Cardiología. Available at: <https://www.revespcardiol.org/>. Accessed 16 Jan 2023.
42. @RevEspCardiol. Twitter. Available at: <https://twitter.com/revespcardiol>. Accessed 16 Jan 2023.
43. Sociedad Española de Cardiología. Blog Revista Española de Cardiología. Available at: <https://secardiologia.es/multimedia/blog/rec>. Accessed 16 Jan 2023.
44. Sanchis J, Avanzas P, Filgueiras-Rama D, García-Pavía Pablo, Sanchis L. Self-reported, nonaudited, multicenter registries. *Rev Esp Cardiol.* 2023;76:58–59.
45. Bowman L, Weidinger F, Albert MA, Fry ETA, Pinto FJ. Clinical Trial Expert Group and ESC Patient Forum. Randomized trials fit for the 21st century. A joint opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation. *Eur Heart J.* 2022. <http://dx.doi.org/10.1093/euroheartj/ehac633>.
46. Fuster V. Impact Factor: A Curious and Capricious Metric. *J Am Coll Cardiol.* 2017;70:1530–1531.
47. REC: CardioClinics. Available in: <https://www.reccardioclinics.org/>. Accessed 16 Jan 2023.
48. REC: Interventional Cardiology. Available in: <https://recintervcardiol.org/>. Accessed 16 Jan 2023.